Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDMTR.L Regulatory News (DMTR)

  • There is currently no data for DMTR

Directorate Changes

19 Oct 2020 07:00

RNS Number : 3991C
DeepMatter Group PLC
19 October 2020
 

19 October 2020

 

DeepMatter Group plc

("DeepMatter", the "Company" or "the Group")

 

Directorate Changes

Appointment of Non-Executive Chair and Chief Financial Officer

 

DeepMatter (AIM: DMTR), the AIM-quoted company focusing on digitising chemistry, is pleased to announce two appointments to the Board, effective on 1 November 2020. Karen Bach will join as Non-Executive Chair and Fraser Benson will join as Chief Financial Officer.

 

Karen Bach brings significant public and private technology expertise, particularly focused on helping young technology businesses deliver on their growth potential, with an understanding of the life sciences through her Non-Executive Directorship at Datapharm Ltd. This is coupled with a strong financial background, having held the CFO role at growing technology businesses; IXEurope Plc, ACS Plc and Kewill Plc; and with blue chip multi-nationals including EDS France, MCI WorldCom, General Motors and Ernst & Young. Karen is currently Chair of Amino Technologies Plc and Consult Red Ltd and Non-Executive Director of Escape Hunt Plc. As well as advising businesses, Karen is a member of the 30% Club, which supports boards to appoint more female directors and increase the pipeline of upcoming female talent at board and senior management levels.

 

Karen has confirmed she intends to subscribe for 500,000 new ordinary shares in the Company at a price of 2.5p per share, prior to her starting date. A further announcement in relation to the subscription will be issued in due course.

 

Fraser Benson has 17 years of accounting experience and significant exposure to fast-growing software businesses having worked at Tradeweb Inc., a NASDAQ listed electronic fixed income and derivatives trading platform, for eight years, latterly as Finance Director, Europe and Asia, supporting the Group's international growth. Previous experience includes working with a range of organisations from FTSE 100 companies through to Venture Capital backed businesses across multiple sectors.

 

Fraser succeeds Lauren Lees, who stood down from the board of directors effective from today. Having seen the Company through to commercialisation, the Board thanks Lauren for her contribution to DeepMatter and wishes her all the very best for the future.

 

Mark Warne, Chief Executive Officer of DeepMatter commented: "I am delighted to welcome Karen and Fraser to the Board as Non-Executive Chair and Chief Financial Officer, respectively.

 

Karen's wealth of experience in working with growth companies, as well as her enthusiasm in the technology sector, resonates with our long-term strategic goal to digitise chemistry while Fraser's experience of working in fast growth businesses means that he has skills and knowledge to share with DeepMatter. We look forward to working with Karen and Fraser as we scale up the business and enter new territories."

 

The following information regarding the appointment of Karen Bach, aged 50, is disclosed under Schedule 2(g) of the AIM Rules for Companies:

 

Current directorships and/or partnerships

Former directorships and/or partnerships (within the last five years):

Purnoma Ltd

Amino Technologies Plc

Escape Hunt Plc

Datapharm Ltd

Red Embedded Consulting Ltd

 

Red Arc (TP) Limited

Red Arc Developments Limited

eLearning-Foundation (also known as Learning Foundation Limited and Learning Foundation)

KalliKids Ltd

KK Cura Ltd

IXCellerate Ltd

KRM22 Central Ltd

KRM22 Development Ltd

Sleeping Lamp Ltd

KRM22 Plc

 

Karen was a director of GalaxyLife Limited, which was a company that entered liquidation.

 

Fraser Benson, aged 41, holds no other current directorships, nor has he held a directorship during the five years prior to his appointment. He holds no interest in ordinary shares of the Company. There are no further disclosures to be made in accordance with Rule 17 and paragraph (g) of Schedule 2 of the AIM Rules for Companies.

 

For more information, please contact:

DeepMatter Group plc

T: 0141 548 8156

Mark Warne, Chief Executive Officer

 

 

 

 

Canaccord Genuity Limited (Nominated Advisor and Broker)

 

T: 020 7523 8000

Bobbie Hilliam / Angelos Vlatakis

 

 

Alma PR

T: 020 3405 0205

Caroline Forde / Harriet Jackson / Kieran Breheny

deepmatter@almapr.co.uk

 

 

About DeepMatter Group plc 

DeepMatter's long term strategy is to integrate chemistry with technology, thereby enabling a greater use of artificial intelligence and reaching a point where chemicals can be autonomously synthesised through robotics. In the near term this involves the provision of an integrated software, hardware and artificial intelligence enabled platform, DigitalGlassware™, to scientists across research and process development sectors. 

 

The DigitalGlassware™ platform allows chemistry experiments to be accurately and systematically recorded, coded and entered into a shared data cloud. The platform is designed to enable chemists to work together effectively; sharing the details of their experiments from anywhere and in real-time, so that work is not needlessly duplicated, time and money wasted, and ultimately so new discoveries may be made faster. 

 

Visit: www.deepmatter.io and follow @deepmattergroup

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEAEEPFSNEFFA
Date   Source Headline
24th Jan 20228:50 amRNSHolding(s) in Company
24th Jan 20227:00 amRNSHolding(s) in Company
20th Jan 202212:15 pmRNSResult of General Meeting
20th Jan 20227:00 amRNSResult of Open Offer - Correction
19th Jan 202211:30 amRNSResult of Open Offer
4th Jan 20221:30 pmRNSPosting of Circular and Notice of GM
29th Dec 20214:36 pmRNSPrice Monitoring Extension
24th Dec 20217:00 amRNSPlacing, Subscription and Open Offer
17th Dec 20215:00 pmRNSBusiness Update and Financing
22nd Oct 20217:00 amRNSAppointment of new Scientific Advisory Board
21st Oct 20218:00 amRNSDigitalGlassware® platform trial with Aurigene
28th Sep 20217:00 amRNSCollaboration
22nd Sep 20217:00 amRNSHalf Year Results
14th Sep 202110:30 amRNSNotice of Half Year Results
8th Sep 20211:30 pmRNSHolding(s) in Company
18th Aug 20217:00 amRNSAdvisory Board Appointment
5th Aug 20217:00 amRNSCollaboration with the University of Cambridge
12th Jul 20217:00 amRNSAppointment of Non-Executive Director
30th Jun 20213:34 pmRNSResult of AGM
22nd Jun 20217:00 amRNSChanges to 2021 AGM Arrangements
17th Jun 20217:00 amRNSCollaboration with the University of Leeds
8th Jun 20213:16 pmRNSPosting of ARA and Updated Notice of AGM
1st Jun 20217:00 amRNSFinal Results
24th May 20217:00 amRNSNotice of Results and Investor Presentation
6th May 20213:43 pmRNSHolding(s) in Company
7th Apr 20217:00 amRNSCollaboration with the University of Nottingham
11th Mar 20217:00 amRNSCo-distribution agreement with Elemental Machines
9th Mar 20217:00 amRNSDirectorate Change
20th Jan 20217:00 amRNSAgreement with Merck's Life Sciences business
19th Jan 20217:00 amRNSHolding(s) in Company
8th Jan 20212:00 pmRNSPrice Monitoring Extension
18th Dec 202010:30 amRNSGrant of PDMR Options
17th Dec 20207:00 amRNSMulti-year contract with Thieme Chemistry
26th Oct 202011:05 amRNSSecond Price Monitoring Extn
26th Oct 202011:00 amRNSPrice Monitoring Extension
21st Oct 20207:00 amRNSIssue of Shares and Total Voting Rights
19th Oct 20207:00 amRNSDirectorate Changes
16th Oct 20207:00 amRNSStrong adoption of ICSYNTH
2nd Oct 20202:05 pmRNSSecond Price Monitoring Extn
2nd Oct 20202:00 pmRNSPrice Monitoring Extension
1st Oct 20208:00 amRNSGrant of Options
29th Sep 20207:00 amRNSHolding(s) in Company
23rd Sep 20201:40 pmRNSHolding(s) in Company
22nd Sep 20204:29 pmRNSHolding(s) in Company
22nd Sep 20204:00 pmRNSHolding(s) in Company
22nd Sep 202010:32 amRNSHolding(s) in Company
15th Sep 20208:08 amRNSIssue of Shares and Total Voting Rights
10th Sep 20207:00 amRNSHalf-year Report
4th Sep 20208:26 amRNSHolding(s) in Company
3rd Sep 20207:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.